• Latest
  • Sectors
    • Pharma
    • Biotech
    • MedTech
    • Regulation & Industry
  • In-House
  • Careers
  • Events
    • Events
    • Events Videos
    • Webinars
  • Insights
    • Whitepapers
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Plastic surgery clinic targets former employees in copyright and TM suit
trademark-istock-508118711-timarbaev-
timarbaev / iStockphoto.com
11 January 2019MedTech

Plastic surgery clinic targets former employees in copyright and TM suit

A New York-based plastic surgery clinic has taken legal action against two former employees and a rival clinic for copyright infringement, trademark counterfeiting and dilution, and cybersquatting.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

MedTech
Sun Pharma import ban back in force after Squires intervention
3 September 2026   A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026   The European court has backed Abbott in a dispute over glucose-monitoring technology, while offering guidance on a key added-matter issue.
MedTech
Invisalign maker secures first China win against clear aligner rival
13 August 2026   Clear aligner rivals are fighting over orthodontic technology across several major markets and the latest development in China has raised the stakes.


Editor's picks

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

Editor's picks

Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

More features

G 1/25: EPO settles controversial patent description question
California votes for law to restrict use of genAI by lawyers
10x Genomics wins latest round in Parse patent dispute
Sun Pharma import ban back in force after Squires intervention
White & Case life sciences co-leader moves firms
‘Busiest’ US district patent judge swaps bench for private practice
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Pinsents expands German patent practice with partner duo

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin